STK11 and non-small cell lung carcinoma: Genetic ablation of STK11 in animal models directly promotes resistance to anti-PD-1 therapies, and in a cohort of NSCLC patients, STK11mut was associated with PD-L1 deletion, suggesting STK11 is related to PD-L1 expression and ICIs resistance.